Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Tenax Therapeutics (NASDAQ: TENX) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025.

Rhea-AI Summary

Tenax Therapeutics (NASDAQ: TENX) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. The company's presentation is a fireside chat on November 10, 2025 at 4:00 p.m. ET, featuring Chris Giordano, President & Chief Executive Officer, and Stuart Rich, M.D., Chief Medical Officer. A live webcast and archived replay will be available on the company's investor relations webpage.

Argus Nov 3 session

-2.32% close to close Open Argus

Details

News Market Reaction – TENX

On Nov 3, the day this news came out, TENX closed 2.32% below the previous close.

Data tracked by StockTitan Argus for the Nov 3 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2^nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.

Details of presentation:

Format: Fireside chat

Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer

Date and Time: November 10, 2025, at 4:00 p.m. ET

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Argot Partners
tenax@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Tenax Therapeutics (TENX) present at the Guggenheim Healthcare Innovation Conference?

Tenax will present in Boston on November 10, 2025 at 4:00 p.m. ET during the November 10-12 conference.

Who will participate in the Tenax (TENX) presentation on November 10, 2025?

The fireside chat will feature Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer.

How can investors watch Tenax Therapeutics (TENX) at the Guggenheim conference?

A live webcast and an archived replay will be accessible from Tenax Therapeutics' investor relations webpage.

What is the format of Tenax Therapeutics' (TENX) presentation at the Guggenheim conference?

The presentation is scheduled as a fireside chat featuring company executives.

Will Tenax (TENX) share clinical or financial data during the November 10, 2025 presentation?

The announcement lists presenters, format, date, and webcast access but does not specify any clinical or financial data to be presented.

Where can I find the archived webcast of Tenax Therapeutics' (TENX) Guggenheim presentation after November 10, 2025?

The archived webcast will be posted on Tenax Therapeutics' investor relations webpage after the live event.